---
title: "Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305581132.md"
description: "Hansoh Pharmaceutical announced that three new indications for its innovative medicines, Ameile and XINYUE, have been added to the 2026 National Reimbursement Drug List (NRDL). The update also covers renewals for existing indications of Ameile, XINYUE, Hansoh Xinfu, and Fulaimei, with expanded coverage for the latter. Additionally, Saint Luolai and Hengmu remain in NRDL agreements, Mailingda is included in category B, and all approved indications of Hansoh's marketed innovative medicines are now covered, enhancing patient access."
datetime: "2026-11-15T10:38:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305581132.md)
  - [en](https://longbridge.com/en/news/305581132.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305581132.md)
generator: "portal-rs"
---

# Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an announcement.

Three new indications for Hansoh’s innovative medicines were added to the 2026 National Reimbursement Drug List: Ameile with pemetrexed and platinum-based chemotherapy as first-line treatment for eligible adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, and XINYUE for adult IgG4-related disease and antibody-positive adult generalized myasthenia gravis.

The renewal also covers four remaining Ameile indications, one remaining XINYUE indication, Hansoh Xinfu and Fulaimei, with Fulaimei’s medical-insurance payment scope expanded. Saint Luolai and Hengmu remain within NRDL agreements, while Mailingda is included in category B; Hansoh stated that all approved indications of its marketed innovative medicines are included, helping improve patients’ affordability and access.

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization](https://longbridge.com/en/news/305569307.md)
- [Hansoh Strikes Multibillion-Dollar ADC Pact With Roche to Expand Global Footprint](https://longbridge.com/en/news/302277319.md)
- [Hansoh Pharma's dalmelitinib-aumolertinib improves progression-free survival in Phase 3 lung cancer trial](https://longbridge.com/en/news/303061643.md)
- [Hansoh Pharmaceutical Group Company Limited (3692) Receives a Buy from Goldman Sachs](https://longbridge.com/en/news/302442690.md)
- [Hansoh Pharma's Ris-Rez cuts progression or death risk by 67% in Phase 3 osteosarcoma trial](https://longbridge.com/en/news/303142954.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**